Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial

Fig. 2

a Mammography of the left breast of a patient in the case group in standard craniocaudal (CC) view shows large irregular mass (arrow) with multiple micro calcifications (inlet: X80). b, c In the same patient, sonography evaluation of the mass before (b) and after (c) neoadjuvant chemotherapy regimen shows significant decrease in the size of the mass (arrows) without complete clinical response. d, e Histopathological evaluation of the tru-cut biopsy of the same patient shows high cellular tumor with Nottingham grade III/III (H & E staining X100, X400 respectively). f Tumor cells with intratumoral infiltrating lymphocytes (TILs) as are shown by arrow (H & E staining. X400). g Immunohistochemical staining of the pre-treatment biopsy for ki-67 antibody shows high proliferative index (X400). h, i Histopathological evaluation of the surgical specimen of the same patient shows fibrotic tumor bed with no residual tumor following second-line neoadjuvant chemotherapy (Pathologic complete response, Residual cancer burden:0) (H & E staining. X40, X400 respectively)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us